This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics
11-13 November 2025
Congress Center BaselBasel, Switzerland

Matthew Quinn
Manager, Analytical Development, Global Nucleic Acid Therapies at Novo Nordisk
Speaker

Profile

18yrs in Pharmaceutical sciences. The first 3yrs were in contract analytical, supporting various pharmaceutical companies in unknown analysis and ID, method development and validation. I then moved onto 5yrs in “first to file” small molecule generics at Hospira where I conducted impurity structure and elucidation, method development and analytical lead. From there I went onto Corden Pharma Boulder CO for 5yrs where I was responsible for downstream peptide purification as well as analytical development and most recently, 5yrs now with Dicerna/NovoNordisk as the analytical development lead and most recently AD Manager for highly modified Oligonucleotides.

Agenda Sessions

  • A New Strategy for Diastereomer Profiling: The Overlapping Fragment Approach

    14:00